NCT03843528View on ClinicalTrials.gov

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

July 30, 2026

Study Completion Date

October 30, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesMixed Phenotype Acute LeukemiaJuvenile Myelomonocytic Leukemia
Interventions
DRUG

Vorinostat

Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.

DRUG

Azacitidine Injection

Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.

Trial Locations (1)

33701

Johns Hopkins All Children's Hospital, St. Petersburg

All Listed Sponsors
lead

Johns Hopkins All Children's Hospital

OTHER